RxDoctor Payments Data

Phillip King, MD

Internal Medicine · Salinas, CANPI 1710961552

Payments from drug & device makers

$9,398in general payments, 2019–2025

Across 546 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$931
  • GSK$886
  • Lilly USA, LLC$835
  • AstraZeneca$693
  • Novo Nordisk$680
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$9,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,398 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$479,610
Medicare patients
1,184
Services billed
13,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin203$220,943
TrulicityDulaglutide66$105,915
MounjaroTirzepatide64$74,914
OzempicSemaglutide44$65,868
EliquisApixaban63$57,426
JanuviaSitagliptin Phosphate20$31,486
RybelsusSemaglutide13$31,400
XareltoRivaroxaban23$24,226
InvokanaCanagliflozin23$18,648
LinzessLinaclotide18$15,952
MyrbetriqMirabegron21$15,608
Tresiba Flextouch U-100Insulin Degludec28$12,189
Atorvastatin Calcium944$11,802
Rosuvastatin Calcium348$8,759
Levothyroxine Sodium566$8,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$101$220,943203 claims
Lilly USA, LLCTrulicity, Mounjaro$835$180,829130 claims
Novo NordiskOzempic, Rybelsus$680$97,26857 claims
PfizerEliquis$650$57,42663 claims
Johnson & JohnsonXarelto, Invokana$97$42,87446 claims
MerckJanuvia$59$31,48620 claims
AbbVieLinzess, Synthroid$2,130$19,39272 claims
Astellas Pharma US IncMyrbetriq$19$15,60821 claims
Idorsia Pharmaceuticals US IncQuviviq$166$5,21611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →